21.00
0.44 (2.14%)
Previous Close | 20.56 |
Open | 20.87 |
Volume | 171,849 |
Avg. Volume (3M) | 514,301 |
Market Cap | 5,730,878,976 |
Price / Earnings (TTM) | 46.67 |
Price / Earnings (Forward) | 44.25 |
Price / Sales | 5.63 |
Price / Book | 4.72 |
52 Weeks Range | |
Earnings Date | 5 Nov 2024 |
TTM Dividend Yield | 0.27% |
Profit Margin | 10.48% |
Operating Margin (TTM) | 14.99% |
Diluted EPS (TTM) | 0.450 |
Quarterly Revenue Growth (YOY) | 2.40% |
Quarterly Earnings Growth (YOY) | -20.80% |
Total Debt/Equity (MRQ) | 27.60% |
Current Ratio (MRQ) | 1.81 |
Operating Cash Flow (TTM) | 122.33 M |
Levered Free Cash Flow (TTM) | -248.84 M |
Return on Assets (TTM) | 4.97% |
Return on Equity (TTM) | 9.48% |
Market Trend
Short Term | Medium Term | ||
Industry | Medical Instruments & Supplies (US) | Mixed | Mixed |
Medical Instruments & Supplies (Global) | Mixed | Mixed | |
Stock | Stevanato Group S.p.A. | Bullish | Bearish |
AIStockmoo Score
Analyst Consensus | 3.0 |
Insider Activity | NA |
Price Volatility | 1.0 |
Technical Moving Averages | 2.5 |
Technical Oscillators | 2.0 |
Average | 2.13 |
Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables. and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa. |
|
Sector | Healthcare |
Industry | Medical Instruments & Supplies |
Investment Style | Mid Growth |
% Held by Insiders | 2.04% |
% Held by Institutions | 115.33% |
Ownership
Name | Date | Shares Held |
---|---|---|
Jackson Square Partners, Llc | 30 Sep 2024 | 1,905,495 |
Tri Locum Partners Lp | 30 Sep 2024 | 1,867,938 |
Timessquare Capital Management, Llc | 30 Sep 2024 | 1,532,429 |
52 Weeks Range | ||
Price Target Range | ||
High | 28.00 (Wolfe Research, 33.33%) | Buy |
Median | 26.00 (23.81%) | |
Low | 23.00 (Morgan Stanley, 9.52%) | Hold |
Average | 25.67 (22.24%) | |
Total | 2 Buy, 1 Hold | |
Avg. Price @ Call | 22.23 |
Firm | Date | Target Price | Call | Price @ Call |
---|---|---|---|---|
B of A Securities | 13 Dec 2024 | 26.00 (23.81%) | Buy | 23.31 |
Wolfe Research | 13 Dec 2024 | 28.00 (33.33%) | Buy | 23.31 |
Morgan Stanley | 03 Dec 2024 | 23.00 (9.52%) | Hold | 20.07 |
No data within this time range.
Date | Type | Details |
---|---|---|
11 Nov 2024 | Announcement | Stevanato Group to Present at Upcoming Investor Conferences |
05 Nov 2024 | Announcement | Stevanato Group Reports Financial Results for the Third Quarter of 2024 |
22 Oct 2024 | Announcement | Stevanato Group to Report Third Quarter 2024 Financial Results on November 5, 2024 |
TTM Dividend Yield | 0.27% |
3Y Average Dividend Yield | 0.26% |
Payout Ratio | 12.33% |
Expected Next Dividend Payment | Jul 2025 |
Ex Date | Announcement Date | Payment Date | Details |
---|---|---|---|
04 Jun 2024 | 10 Apr 2024 | 15 Jul 2024 | 0.0573 Cash |
07 Jun 2023 | 05 Apr 2023 | 17 Jul 2023 | 0.0577 Cash |
13 Jun 2022 | 11 Apr 2022 | 13 Jul 2022 | 0.0546 Cash |
Annual Dividend Yield
Year | Annual Dividend ($) | Frequency/Year | Yield % |
---|---|---|---|
2024 | 0.057 | 1 | 0.26 |
2023 | 0.058 | 1 | 0.21 |
2022 | 0.055 | 1 | 0.30 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2025 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |